Sort
82,697 grants matching “vaccine development”
Assessment of the Immune-mediated Protection and Pathology Conferred by Candidate Filovirus Vaccines
$1,160,539National Institute Of Allergy And Infectious Diseases · Y01 · FY2018 · AI
Production of Pedigreed SPF Rhesus Macaques
$1,160,398Jeffrey A Roberts · University Of California At Davis · U42 · FY2016 · OD
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
$1,160,092Quarraisha Abdool Karim · Centre/Aids Programme/Res/South Africa · UM1 · FY2015 · AI
Development/Production-Alternative Serotype HIV Recombinant Adenoviral Vaccine
$1,159,913Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2011 · AI
A Vaccine for Schistosomiasis, "SchistoShield"
$1,159,786Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2016 · AI
Discovery and Targeting of West Nile Virus Epitopes
$1,159,715William Hildebrand · University Of Oklahoma Hlth Sciences Ctr · U01 · FY2012 · AI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,159,409John Givens · Starks Associates, Inc. · N01 · FY2018 · AI
Dimandelic Acid Ethers As Topical Microbicides For HIV
$1,159,341Mount Sinai School Of Medicine Of Nyu · P01 · FY2003 · HD
Experimental Therapeutics of Pediatric Hematopoietic Malignancies
$1,159,275Alan S Wayne · Division Of Clinical Sciences - Nci · ZIC · FY2009 · CA
Preclinical development of a vaccine for Nipah virus
$1,159,045Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2023 · AI
Addressing COVID-19 Testing Disparities in Vulnerable Populations Using a Community JITAI (Just in Time Adaptive Intervention) Approach - Phase II
$1,158,954David D McPherson · University Of Texas Hlth Sci Ctr Houston · UL1 · FY2022 · TR
Esophageal gland-mediated immune evasion by the human parasite Schistosoma mansoni
$1,158,837Jayhun Lee · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · AI
Crossprotective CTL Against Influenza
$1,158,777Ellis L Reinherz · Dana-Farber Cancer Inst · U01 · FY2011 · AI
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
$1,158,564Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2020 · AI
Integrated Services Core
$1,158,560William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2023 · AI
Omics, Bioinformatics, and Data Management Core
$1,158,449Michael J Gale · Oregon Health & Science University · P01 · FY2023 · AI
Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors
$1,158,393Kenner Rice · National Institute On Drug Abuse · ZIA · FY2014 · DA
Immunotherapeutic Approaches for AIDS
$1,158,141George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Metabolic and Immunologic Effects of Meditation
$1,158,102Frederick M Hecht · University Of California, San Francisco · P01 · FY2011 · AT
Personalized Cystic Fibrosis Therapy and Research Center
$1,158,088Anjaparavanda P Naren · Cincinnati Childrens Hosp Med Ctr · P30 · FY2020 · DK
Comprehensive SDSU/UCSD Cancer Center Partnership 1 of 2
$1,158,050Elva M Arredondo · San Diego State University · U54 · FY2012 · CA
Vermont Immunobiology / Infectious Diseases Center
$1,157,709Ralph C. Budd · University Of Vermont & St Agric College · P30 · FY2016 · GM
Preclinical development of a vaccine for Nipah virus
$1,157,701Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2025 · AI
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE
$1,157,646Nabi Biopharmaceuticals · U19 · FY2003 · DA
NATURAL HISTORY OF HPV--INFECTION TO NEOPLASIA
$1,157,602University Of California San Francisco · R01 · FY2001 · CA